Burrage Lindsay C, Guillerman R Paul, Das Shailendra, Singh Shipra, Schady Deborah A, Morris Shaine A, Walkiewicz Magdalena, Schecter Marc G, Heinle Jeffrey S, Lotze Timothy E, Lalani Seema R, Mallory George B
Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX; Texas Children's Hospital, Houston, TX.
Department of Radiology, Baylor College of Medicine, Houston, TX.
J Pediatr. 2017 Jul;186:118-123.e6. doi: 10.1016/j.jpeds.2017.03.045. Epub 2017 Apr 28.
To describe a series of patients with pathogenic variants in FLNA and progressive lung disease necessitating lung transplantation.
We conducted a retrospective chart review of 6 female infants with heterozygous presumed loss-of-function pathogenic variants in FLNA whose initial presentation was early and progressive respiratory failure.
Each patient received lung transplantation at an average age of 11 months (range, 5-15 months). All patients had pulmonary arterial hypertension and chronic respiratory failure requiring tracheostomy and escalating levels of ventilator support before transplantation. All 6 patients survived initial lung transplantation; however, 1 patient died after a subsequent heart-lung transplant. The remaining 5 patients are living unrestricted lives on chronic immunosuppression at most recent follow-up (range, 19 months to 11.3 years post-transplantation). However, in all patients, severe ascending aortic dilation has been observed with aortic regurgitation.
Respiratory failure secondary to progressive obstructive lung disease during infancy may be the presenting phenotype of FLNA-associated periventricular nodular heterotopia. We describe a cohort of patients with progressive respiratory failure related to a pathogenic variant in FLNA and present lung transplantation as a viable therapeutic option for this group of patients.
描述一系列患有FLNA基因致病性变异且患有需要肺移植的进行性肺部疾病的患者。
我们对6名患有FLNA基因杂合性假定功能丧失致病性变异的女婴进行了回顾性病历审查,她们最初的表现为早期进行性呼吸衰竭。
每位患者平均在11个月大时(范围为5 - 15个月)接受了肺移植。所有患者在移植前均患有肺动脉高压和慢性呼吸衰竭,需要气管切开术和逐渐增加的呼吸机支持水平。所有6名患者在初次肺移植后存活;然而,1名患者在随后的心肺移植后死亡。其余5名患者在最近一次随访时(移植后19个月至11.3年)在慢性免疫抑制下过着不受限制的生活。然而,在所有患者中,均观察到严重的升主动脉扩张并伴有主动脉反流。
婴儿期进行性阻塞性肺病继发的呼吸衰竭可能是FLNA相关室管膜下结节性异位的表现型。我们描述了一组与FLNA基因致病性变异相关的进行性呼吸衰竭患者,并提出肺移植是这组患者可行的治疗选择。